Other formats:
BibTeX
LaTeX
RIS
@article{1216811, author = {Valent, Peter and Sadovnik, Irina and Ráčil, Zdeněk and Herrmann, Harald and Blatt, Katharina and CernyandReiterer, Sabine and Eisenwort, Gregor and Lion, Thomas and Holyoake, Tessa and Mayer, Jiří}, article_location = {HOBOKEN}, article_number = {12}, doi = {http://dx.doi.org/10.1111/eci.12368}, keywords = {Diagnostics; leukaemia; leukaemic stem cells; stem cell; phenotyping}, language = {eng}, issn = {0014-2972}, journal = {European Journal of Clinical Investigation}, title = {DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia}, volume = {44}, year = {2014} }
TY - JOUR ID - 1216811 AU - Valent, Peter - Sadovnik, Irina - Ráčil, Zdeněk - Herrmann, Harald - Blatt, Katharina - Cerny-Reiterer, Sabine - Eisenwort, Gregor - Lion, Thomas - Holyoake, Tessa - Mayer, Jiří PY - 2014 TI - DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia JF - European Journal of Clinical Investigation VL - 44 IS - 12 SP - 1239-1245 EP - 1239-1245 PB - WILEY-BLACKWELL SN - 00142972 KW - Diagnostics KW - leukaemia KW - leukaemic stem cells KW - stem cell KW - phenotyping N2 - The concept of leukaemic stem cells (LSCs) has been developed to explain the complex cellular hierarchy and biology of leukaemias and to screen for pivotal targets that can be employed to improve drug therapies through LSC eradication in these patients. Some of the newly discovered LSC markers seem to be expressed in a disease-specific manner and may thus serve as major research tools and diagnostic parameters. A useful LSC marker in chronic myeloid leukaemia (CML) appears to be CD26, also known as dipeptidylpeptidase IV. Expression of CD26 is largely restricted to CD34(+)/CD38(-) LSCs in BCR/ABL1(+) CML, but is not found on LSCs in other myeloid or lymphoid neoplasms, with the exception of lymphoid blast crisis of CML, BCR/ABL1(p210)+ acute lymphoblastic leukaemia, and a very few cases of acute myeloid leukaemia. Moreover, CD26 usually is not expressed on normal bone marrow (BM) stem cells. Functionally, CD26 is a cytokine-targeting surface enzyme that may facilitate the mobilization of LSCs from the BM niche. In this article, we review our current knowledge about the biology and function of CD26 on CML LSCs and discuss the diagnostic potential of this new LSC marker in clinical haematology. ER -
VALENT, Peter, Irina SADOVNIK, Zdeněk RÁČIL, Harald HERRMANN, Katharina BLATT, Sabine CERNY-REITERER, Gregor EISENWORT, Thomas LION, Tessa HOLYOAKE and Jiří MAYER. DPPIV (CD26) as a novel stem cell marker in Ph plus chronic myeloid leukaemia. \textit{European Journal of Clinical Investigation}. HOBOKEN: WILEY-BLACKWELL, 2014, vol.~44, No~12, p.~1239-1245. ISSN~0014-2972. Available from: https://dx.doi.org/10.1111/eci.12368.
|